Predict your next investment

Venture Capital
biomedicine.ch

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Funds

1

About Biomedicine

International BM Biomedicine Holdings is an investment firm which invests in leading technology-based, research-oriented biotechnology companies in the pharmaceutical area. The firm uses Global Biomedical Partners as its exclusive investment advisor to perform due diligence and make recommendations that IBMH acts on.

Biomedicine Headquarter Location

Nauenstrasse 41

Basel, 4002,

Switzerland

41 61 270 8210

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Biomedicine News

As Per Latest Report: Biopharmaceutical and Biomedicine Market Estimated to Generate a Revenue of US$ 800.0 Bn with Growing at a CAGR of 9.4% from 2021 to 2027

Sep 22, 2021

Search jobs 22-Sep-2021 As Per Latest Report: Biopharmaceutical and Biomedicine Market Estimated to Generate a Revenue of US$ 800.0 Bn with Growing at a CAGR of 9.4% from 2021 to 2027 CMI published a business research report on “Biopharmaceuticals and Biomedicine Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2021–2027”. Biopharmaceuticals and Biomedicine with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items. Biopharmaceuticals and Biomedicine Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Biopharmaceuticals and Biomedicine Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report. Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/18 Biopharmaceuticals are drugs that are partially or fully manufactured, or extracted from biological sources. Biopharmaceuticals contain variety of products such as monoclonal antibodies, vaccines, recombinant human insulin, human growth hormone, erythropoietin, interferon, colony stimulating factor, and blood factors. Currently, biopharmaceuticals accounts for over one-fifth of pharmaceutical market, and this percentage share of biopharmaceutical is expected to increase, owing to its advantage compared to totally synthesize pharmaceutical drugs. Fewer side effects, high effectiveness and potent action, and ability to cure the disease rather than treat are some of the major advantages of these drugs. Continuous launch, approvals, and robust pipeline of biopharmaceutical products is expected to drive growth of the market  In the recent past, regulatory bodies in key regions such as U.S. and Europe have approved a number of biopharmaceutical products, which have been subsequently launched in the market. For instance in 2017, Johnson & Johnson received U.S. FDA approval for its new immunology product—Tremfya (Guselkumab)—used for the treatment of moderate to severe plaque psoriasis. In 2017, Sanofi S.A. received U.S. FDA approval for its new Admelog, a rapid-acting insulin, indicated for the management of blood sugar levels at mealtime. In 2017, U.S. FDA approved GlaxoSmithKline Plc.’s New Shingrix, a shingles vaccine. FDA approved this vaccine to be used by people aged 50 years and above as an immunization against the painful condition caused by latent varicella infection. In 2017, Spark Therapeutics, Inc. received FDA approval for its LUXTURNA (voretigene neparvovec-rzyl). LUXTURNA is first gene therapy and pharmacologic treatment for an inherited retinal disease (IRD), and the first approved adeno-associated virus (AAV) vector gene therapy in the U.S. In 2017, HumanZyme Inc. launched its new HumanKine Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is an interferon of type I family, which activates Th1-type innate immune responses against viral and bacterial infection. In 2016, Novo Nordisk A/S launched its new next-generation once-daily basal insulin Tresiba (insulin degludec) in the U.S. market and in 2017, Nordisk A/S received China Food and Drug Administration (CFDA) approval to market its Tresiba (insulin degludec) in China. Such frequent launches and approvals of novel products is expected to drive growth of the market in the near future. The global biopharmaceutical and biomedicine market was valued at US$ 358.4 Bn in 2016 and is expected to witness a CAGR of 9.4% over the forecast period (2017–2025). Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/18 Main points in Biopharmaceuticals and Biomedicine Market Report Table of Content Chapter 1 Industry Overview 1.5 Biopharmaceuticals and Biomedicine Market Size Analysis from 2021 to 2027 11.6 COVID-19 Outbreak: Biopharmaceuticals and Biomedicine Industry Impact Chapter 2 Biopharmaceuticals and Biomedicine Competition by Types, Applications, and Top Regions and Countries 2.1 Biopharmaceuticals and Biomedicine (Volume and Value) by Type 2.3 Biopharmaceuticals and Biomedicine (Volume and Value) by Regions Chapter 3 Production Market Analysis 3.1 Production Market Analysis Chapter 4 Biopharmaceuticals and Biomedicine Sales, Consumption, Export, Import by Regions (2016-2021) Chapter 5 North America Biopharmaceuticals and Biomedicine Market Analysis Chapter 6 East Asia Biopharmaceuticals and Biomedicine Market Analysis Chapter 7 Europe Biopharmaceuticals and Biomedicine Market Analysis Chapter 8 South Asia Biopharmaceuticals and Biomedicine Market Analysis Chapter 9 Southeast Asia Biopharmaceuticals and Biomedicine Market Analysis Chapter 10 Middle East Biopharmaceuticals and Biomedicine Market Analysis Chapter 11 Africa Biopharmaceuticals and Biomedicine Market Analysis Chapter 12 Oceania Biopharmaceuticals and Biomedicine Market Analysis Chapter 13 South America Biopharmaceuticals and Biomedicine Market Analysis Chapter 14 Company Profiles and Key Figures in Biopharmaceuticals and Biomedicine Business Chapter 15 Biopharmaceuticals and Biomedicine Market Forecast (2021-2027) Chapter 16 Conclusions About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services. Contact:

Biomedicine Investments

2 Investments

Biomedicine has made 2 investments. Their latest investment was in Artemis Pharmaceuticals as part of their Series B on April 4, 2000.

CBI Logo

Biomedicine Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/5/2000

Series B

Artemis Pharmaceuticals

$12.56M

No

3i Group, Advent International, Atlas Venture, Global Life Science Ventures, Oxford Bioscience Partners, Sal. Oppenheim Private Equity Partners, and Undisclosed Investors

1

9/16/1998

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/5/2000

9/16/1998

Round

Series B

Series A

Company

Artemis Pharmaceuticals

Subscribe to see more

Amount

$12.56M

$99M

New?

No

Subscribe to see more

Co-Investors

3i Group, Advent International, Atlas Venture, Global Life Science Ventures, Oxford Bioscience Partners, Sal. Oppenheim Private Equity Partners, and Undisclosed Investors

Sources

1

10

Biomedicine Portfolio Exits

1 Portfolio Exit

Biomedicine has 1 portfolio exit. Their latest portfolio exit was Artemis Pharmaceuticals on April 01, 2001.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/1/2001

Acquired

Undisclosed Investors

1

Date

4/1/2001

Exit

Acquired

Companies

Valuation

Acquirer

Undisclosed Investors

Sources

1

Biomedicine Fund History

1 Fund History

Biomedicine has 1 fund, including Biomedicine LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/1/2000

Biomedicine LP

Buyouts & Acquisitions

$73.53M

1

Closing Date

1/1/2000

Fund

Biomedicine LP

Fund Type

Buyouts & Acquisitions

Status

Amount

$73.53M

Sources

1

Biomedicine Team

4 Team Members

Biomedicine has 4 team members, including current Chief Executive Officer, Patrick Weber.

Name

Work History

Title

Status

Patrick Weber

Chief Executive Officer

Current

Richard J Dold

Chief Executive Officer

Former

Stefan Ryser

Chief Executive Officer

Former

Michael E Meyers

Managing Partner

Former

Name

Patrick Weber

Richard J Dold

Stefan Ryser

Michael E Meyers

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Managing Partner

Status

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.